You are here

myelofibrosis

In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use

In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use

Fierce Pharma

Flag link:

Incyte Abandons Phase III Trial for Myelofibrosis Treatment

Incyte Abandons Phase III Trial for Myelofibrosis Treatment

BioSpace

clinical trials

Flag link:

GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision

GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision

Fierce Biotech

Sierra Oncology

Flag link:

Galecto links blood cancer prospect to reduced fibrosis in early data drop

Galecto links blood cancer prospect to reduced fibrosis in early data drop

Fierce Biotech

clinical trials

Flag link:

AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark

AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark

Fierce Biotech

Flag link:

A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers

A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers

Endpoints

Bristol Myers Squibb

Flag link:

Imago BioSciences Advances Myelofibrosis Trials, With Phase IIb Prelim Readout Imminent

Imago BioSciences Advances Myelofibrosis Trials, With Phase IIb Prelim Readout Imminent

BioSpace

clinical trials

Flag link:

Celgene wins approval for drug key to Bristol buyout

Celgene wins approval for drug key to Bristol buyout

Biopharma Dive

Bristol-Myers Squibb

Flag link:

Sierra doubles down on ex-Gilead drug, deprioritizes other assets

Sierra doubles down on ex-Gilead drug, deprioritizes other assets

Fierce Biotech

Sierra Oncology

Gilead Sciences

Flag link:

Did Geron's Big Announcement Just Go Unnoticed?

Did Geron's Big Announcement Just Go Unnoticed?

Yahoo/Motley Fool

Flag link:

Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug

Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug

Xconomy

Gilead Sciences

Sierrra Oncology

Flag link:

A Huge Decision Is on Tap for This Little Biotech Stock

A Huge Decision Is on Tap for This Little Biotech Stock

Yahoo/Motley Fool

Flag link:

Four years after it imploded at Sanofi, John Hood is resurrecting the myelofibrosis drug fedratinib

Four years after it imploded at Sanofi, John Hood is resurrecting the myelofibrosis drug fedratinib

Endpoints

Impact Biomedicines

Flag link:

Gilead Fails to Beat Incyte’s Jakafi Drug

Gilead Fails to Beat Incyte’s Jakafi Drug

Investopedia

Gilead Sciences

Flag link:

Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal

Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal

Endpoints

Flag link:

Geron shares jump after two positive drug studies

Geron shares jump after two positive drug studies

Marketwatch

essential thrombocythemia

Flag link:

ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival

ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival

TheStreet.com

Flag link:

Baxter and its controversial partner CTI claim a win in PhIII blood cancer study

Baxter and its controversial partner CTI claim a win in PhIII blood cancer study

Fierce Biotech

Flag link:

Johnson & Johnson (JNJ) Strikes $935 Million Deal With Geron Corporation (GERN) To Co-Develop Imetelstat

Johnson & Johnson (JNJ) Strikes $935 Million Deal With Geron Corporation (GERN) To Co-Develop Imetelstat

Bidness Etc.

Flag link:

Incyte Building Blockbuster Drug One Disease At A Time

Incyte Building Blockbuster Drug One Disease At A Time

Investors.com

Flag link:

Pages